Sign In
Last checked at 
27 Oct 2017 11:30
Proteome Sciences plc
("Proteome Sciences" or the "Company")
Director/PDMR Shareholding
The Company has received notification from Vulpes Life Sciences Fund ("Vulpes") that on 24 October 2017 and 25 October 2017, it purchased 75,000 and 109,460 ordinary shares of 1p each, respectively, in the capital of the Company ("Ordinary Shares") at an average price of 3.18p per Ordinary Share (the "Purchase"). Following the Purchase, Vulpes has a total direct and indirect interest in 55,197,431 equivalent to 18.69% of Proteome Sciences' total issued share capital.
The Company would also like to announce that by virtue of Martin Diggle being a Director of both Vulpes and the Company, he now has an interest in 55,197,431 Ordinary Shares of the Company representing 18.69% of the issued share capital of the Company.
1. | Details of the person discharging managerial responsibilities / person closely associated | |
a) | Name | Vulpes Life Sciences Fund |
2. | Reason for the Notification | |
a) | Position/status | PCA of Martin Diggle (NED) |
b) | Initial notification/Amendment | Initial notification |
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Name | Proteome Sciences plc |
b) | LEI | 213800Q62ICXANKU2986 |
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a) | Description of the Financial instrument, type of instrument | Ordinary Shares of 1p each |
Identification code | GB0003104196 | |
b) | Nature of the transaction | Purchase of shares |
c) | Price(s) and volume(s) | 75,000 Ordinary Shares at 3.11p per Ordinary Share 109,460 Ordinary Shares at 3.25p per Ordinary Share |
d) | Aggregated information: · Aggregated volume · Price |
184,460 Ordinary Shares of 1p each purchased at an average price of 3.18p per Ordinary Share |
e) | Date of the transaction | 24, 25 October 2017 |
f) | Place of the transaction | London Stock Exchange, AIM Market (XLON) |
For further information: Proteome Sciences plc | |
Jeremy Haigh, Chief Executive Officer Tel: +44 (0)20 7043 2116 | |
Ian Pike, Chief Scientific Officer | |
Stefan Fuhrman, Interim Finance Director | |
finnCap Limited (Nominated Adviser/Broker) |
|
Geoff Nash/James Thompson | Tel: +44 (0)20 7220 0500 |
Tony Quirke (broking) IFC Advisory (Financial PR and IR) | |
Tim Metcalfe/Graham Herring/Miles Nolan | Tel: +44 (0)20 3053 8671 |
| |
Notes for editors:
About Proteome Sciences plc. (www.proteomics.com)
Proteome Sciences is a leader in applied proteomics offering high sensitivity, proprietary technologies and workflows for mapping cell signalling pathways (SysQuant®) and for the discovery, validation and assay development of protein biomarkers (TMTcalibrator™). The company has its headquarters in London, UK, with laboratory facilities in Frankfurt, Germany from where the PS Biomarker Services™ division provides outsourced proteomics services and proprietary biomarker assays to biopharmaceutical and diagnostics companies and to academia.
Proteome Sciences has patented a number of novel protein biomarkers for diagnostic and treatment applications in important areas of human therapeutics such as cancer, stroke and Alzheimer's disease, and these are available for license.
Follow the stocks
